Persons with a History of Myocarditis or Pericarditis

Myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining around the heart) have occurred in some people following receipt of mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna).

People with a history of myocarditis or pericarditis after receiving the first dose of an mRNA COVID-19 vaccine:

  • Defer the second dose of an mRNA COVID-19 vaccine. Administration of the second dose of an mRNA COVID-19 vaccine series can be considered in certain circumstances after the episode of myocarditis or pericarditis has completely resolved.

History of myocarditis or pericarditis prior to COVID-19 vaccination

  • May receive any FDA-authorized COVID-19 vaccine after the episode of myocarditis or pericarditis has completely resolved

Inform recipients, especially males 12 through 29 years of age and their parents/legal representative (when relevant) of the possibility of myocarditis or pericarditis following receipt of mRNA COVID-19 vaccines and the need to seek care if symptoms of myocarditis or pericarditis develop after vaccination.

info

Use of mRNA COVID-19 Vaccine After Reports of Myocarditis


back
Next

 

Page last reviewed: October 8, 2021